FBR & Co Analysts Give Abeona Therapeutics Inc. (ABEO) a $15.00 Price Target
Abeona Therapeutics Inc. (NASDAQ:ABEO) has been assigned a $15.00 price target by research analysts at FBR & Co in a note issued to investors on Wednesday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. FBR & Co’s price objective suggests a potential upside of 159.52% from the stock’s previous close.
A number of other equities analysts also recently commented on ABEO. Zacks Investment Research downgraded shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 24th. Maxim Group reissued a “buy” rating on shares of Abeona Therapeutics in a research note on Tuesday, May 24th. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $17.00 price target on shares of Abeona Therapeutics in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $12.40.
Abeona Therapeutics (NASDAQ:ABEO) traded up 15.05% during trading on Wednesday, hitting $6.65. 1,305,808 shares of the stock were exchanged. The stock’s 50 day moving average price is $4.28 and its 200 day moving average price is $3.09. Abeona Therapeutics has a 12 month low of $2.05 and a 12 month high of $6.74. The stock’s market cap is $223.07 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fbr-co-analysts-give-abeona-therapeutics-inc-abeo-a-15-00-price-target-2.html
Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. Analysts forecast that Abeona Therapeutics will post ($0.73) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares during the period. BlackRock Fund Advisors boosted its position in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 23,734 shares during the period. Sabby Management LLC boosted its position in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares during the period. Finally, Royce & Associates LP boosted its position in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares during the period. Hedge funds and other institutional investors own 19.95% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.